Xeltis received CE mark approval for its Axess restorative vascular access conduit for hemodialysis. The company also released 12-month durability data from an EU pivotal trial, reporting secondary patency of 79% and a low patency-related reintervention rate of 1.3 per patient-year. The update also pointed to reduced infection burden versus prior benchmarks, positioning the conduit as a more durable option for long-term dialysis access and potentially fewer repeat procedures for patients. For med-tech investors and providers, CE clearance plus pivotal durability metrics can accelerate adoption in markets where access device performance drives throughput, costs, and patient quality of life.